Trial Profile

Pilot Study of a MUCI Peptide and Poly-ICLC Vaccine for Triple-Negative Breast Cancer.

Status: Completed

Phase of Trial: Phase 0

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cancer vaccine MUC-1 (Primary) ; Poly ICLC (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Early breast cancer; Triple negative breast cancer
Focus Therapeutic Use

Most Recent Events

19 Jul 2018 Status changed from active, no longer recruiting to completed.
19 Jun 2015 Planned primary completion date changed from 1 Dec 2013 to 1 Aug 2015, as reported by ClinicalTrials.gov.
02 Aug 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com